 SAN FRANCISCO, Sept. 07, 2022 GLOBE NEWSWIRE -- 89bio, Inc. Nasdaq: ETNB, a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that Companys Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 4:00 PM ET. 